PubMed HealthSearch

Biomedical subjects

W S Cendrowski

Publications and source records attributed to W S Cendrowski.

17 recordsLinked to original sources

Progression index and disability status in multiple sclerosis: a resurvey of 207 patients in central Poland.

The progression index (disability grade divided by the duration of the disease) and disability status are presented in multiple sclerosis (MS) patients from two hospital series in central Poland. The natural course of 207 patients showed continuously decreasing progression index (PI) from 4.15 after the first year to 0.72 and 0.23 after 10 yr. or 26 yr. respectively. Within the duration of the disease from 1 to 40 years mean PI was 1.12. Among 207 hospitalized patients 156 (75.6%) showed moderately speedy progression with PI 0.21-1.33. Mean neurologic impairment evaluated on Disability Status Scale (DSS) was 6.27 (range 4.40-8.25). Overall neurologic disability slowly increased from 5.82, 6.50, 7.04 at 5 years intervals up to 7.17 after 26 years. Out of 207 patients 127 (71.1%) demonstrated either moderate or severe impairment (4-9 grades at DSS). These figures represent rather biased hospital over-representation of grave cases than more malignant natural course of MS in Poland. It was also considered that very slow PI (0.20 or less) has at least approximately as good prognostic value as Kurtzke's "rule of 5 yr. at DSS". In the present hospital series none of MS patients with low PI - less than or equal to 0.20 - had deteriorated after 26 yr. of the disease beyond 6th grade of DSS.

Adolescent

Pilot-study on large-dose alternate-day steroid therapy in multiple sclerosis.

Twenty-one patients with multiple sclerosis (MS) were given on alternate day larger doses of dexamethasone (4-8 mg) for 1 to 4 cycles and were followed up for an average of 5 months. In the group of 11 patients with relapsing course slightly better improvement was found immediately after first 5 weeks course of alternate-day intensive steroid therapy (ADST) (mean score -1.6 in numerical rating) than in 11 patients taking azathioprine (-0.9). The difference between these two relapsing groups tended to reach the level of statistical significance (p less than 0.10). Long-term effects of ADST or azathioprine treatment in patients with acute relapses were completely negative. The rate of relapse per patient-year was 0.45 in the ADST group and 0.80 in the azathioprine group. This difference was also not significant. Mild side-effects of ADST were found only in 4 patients (19%). Although the number of patients is small and the period of follow-up is limited, it can be assumed that immediate clinical effects of intensive ADST in acute relapses of MS are slightly superior to that of azathioprine. However, ADST did not affect the overall rate of clinical deterioration.

Adolescent